MAP Pharmaceuticals, Inc.

Form 4 May 29, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading FirstMark Capital, L.L.C. Issuer Symbol MAP Pharmaceuticals, Inc. [MAPP] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner __X_ Other (specify Officer (give title 1221 SIXTH AVENUE 05/28/2009 below) below) See Footnote 1 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting NEW YORK, NY 10020 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 4. Securities Acquired (A) 5. Amount of 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Ownership Indirect

(Instr. 3)		any (Month/Day/Year)	Code (Instr. 8)	(Instr. 3,	4 and	5)	Beneficially Owned Following	Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	
Common Stock	05/28/2009		S	900 (2)	` '		2,342,072 (2)	I (2)	Investment Advisor (1)
Common Stock	05/28/2009		S	500 (2)	D	\$ 13.44	2,341,572 (2)	I (2)	Investment Advisor (1)
Common Stock	05/28/2009		S	200 (2)	D	\$ 13.445	2,341,372 (2)	I (2)	Investment Advisor (1)
Common Stock	05/28/2009		S	1,400 (2)	D	\$ 13.45	2,339,972 (2)	I (2)	Investment Advisor $\underline{^{(1)}}$
Common Stock	05/28/2009		S	300 (2)	D	\$ 13.47	2,339,672 (2)	I (2)	Investment Advisor (1)

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

Common Stock	05/28/2009	S	5,100 (2)	D	\$ 13.5	2,334,572 (2) I (2)	Investment Advisor (1)
Common Stock	05/28/2009	S	100 (2)	D	\$ 13.5004	2,334,472 (2) I (2)	Investment Advisor (1)
Common Stock	05/28/2009	S	400 (2)	D	\$ 13.55	2,334,072 (2) I (2)	Investment Advisor (1)
Common Stock	05/28/2009	S	20 (2)	D	\$ 13.585	2,334,052 (2) I (2)	Investment Advisor (1)
Common Stock	05/28/2009	S	30 (2)	D	\$ 13.595	2,334,022 (2) I (2)	Investment Advisor (1)
Common Stock	05/28/2009	S	1,250 (2)	D	\$ 13.6	2,332,772 (2) I (2)	Investment Advisor (1)
Common Stock	05/28/2009	S	1,250 (2)	D	\$ 13.6001	2,331,522 (2) I (2)	Investment Advisor (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.		6. Date Exerc	cisable and	7. Tit.	le and	8. Price of	
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transac	ctionNu	mber	Expiration D	ate	Amou	ınt of	Derivative	
Security	or Exercise		any	Code	of		(Month/Day/	Year)	Unde	rlying	Security	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8	8) Dea	rivative	e		Secur	ities	(Instr. 5)	
	Derivative				Sec	urities			(Instr	. 3 and 4)		
	Security				Ac	quired						
	•				(A)	or						
					` ′	posed						
					of (
						str. 3,						
					•	ind 5)						
					., .	a 5)						
										Amount		
							Date	Expiration		or		
								•	Title	Number		
							Exercisable	Date		of		
				Code	V (A)	(D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
Troporting of the France of France of the Fr	Director	10% Owner	Officer	Other				
FirstMark Capital, L.L.C. 1221 SIXTH AVENUE NEW YORK, NY 10020				See Footnote 1				

Reporting Owners 2

Signatures

/s/ Brian Kempner, Chief Operating Officer & Chief Counsel

05/29/2009

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- FirstMark Capital, L.L.C., a Delaware limited liability company ("FirstMark"), is an investment advisor acting on behalf of its clients' accounts. FirstMark disclaims any obligation to file this report, and this report shall not be deemed an admission that FirstMark is subject to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with respect to the Issuer of such securities.
- (2) FirstMark disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that FirstMark is, for the purposes of the Section 16 of the Exchange Act or otherwise, the beneficial owner of such securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3